AI Scribing Tools Face Regulatory Hurdles
Frimley Health Foundation Trust paused the rollout of an AI scribing tool used for automated clinical notes after the system lacked MHRA Class I medical device status. The issue highlights a gap between rapid product deployment and device regulation when software performs clinical summarisation or documentation tasks. MHRA classification affects procurement, liability and local sign-off; without it, trusts risk non-compliance with medical device rules and potential patient safety questions. For clinicians and procurement teams, the episode underlines the need to check device status, technical documentation and oversight arrangements before trialling ambient voice or auto-scribe features in routine care.
Palantir’s NHS Data Deal Under Fire
Palantir’s Federated Data Platform (FDP) contract with NHS England has drawn continuing parliamentary and public scrutiny. MPs rejected claims that criticism is merely ideologically motivated and are examining contract terms, governance arrangements and a potential break clause. Concerns centre on data access controls, commercial influence over national analytics infrastructure and transparency of decision-making. The debate shows political sensitivity around third-party data platforms and the expectations that national data services operate with tight governance, clear accountability and visible protections for patient information.
What This Means for AI in UK Healthcare
These two developments point to the same lesson: adoption of AI in a public health system depends on regulatory clarity and trust. MHRA classifications, robust procurement checks and explicit governance arrangements are practical prerequisites. Absent those, pilots can be paused and high-profile contracts can attract political challenge, slowing wider adoption.
Practical actions for stakeholders:
- Developers: obtain appropriate MHRA classification and publish technical documentation and validation evidence before deployment.
- Providers: include device-status checks and data-governance reviews in procurement and trial approvals.
- Policymakers: clarify oversight expectations for national platforms and set transparent audit and exit provisions in contracts.
For AI projects to move from pilots to routine use in the NHS, teams must meet regulatory standards and build visible governance that maintains public confidence.
